bioAffinity Technologies, Inc.
NASDAQ: BIAF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Maria Zannes
- Employees
- 57
- Headquarters
- San Antonio, United States
- IPO year
- 2022
- Market cap
- $3.9M
- Website
- https://www.bioaffinitytech.com
Loading BIAF…
Loading profile data…Frequently asked questions about BIAF
What does bioAffinity Technologies, Inc. (BIAF) do?
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted ther...
Where does BIAF trade?
bioAffinity Technologies, Inc. (BIAF) trades on the NASDAQ Capital Market.
What sector is BIAF in?
bioAffinity Technologies, Inc. (BIAF) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of bioAffinity Technologies, Inc.?
Maria Zannes is the chief executive officer of bioAffinity Technologies, Inc. (BIAF).
Where is bioAffinity Technologies, Inc. headquartered?
bioAffinity Technologies, Inc. is headquartered in United States.
Does BIAF pay a dividend?
bioAffinity Technologies, Inc. (BIAF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BIAF go public?
bioAffinity Technologies, Inc. (BIAF) completed its initial public offering in 2022.